Incruse

Incruse

  • July 2018 •
  • 16 pages •
  • Report ID: 5780254 •
  • Format: PDF
Drug Overview
Incruse (umeclidinium; GlaxoSmithKline) is a once-daily long-acting muscarinic antagonist (LAMA) indicated for the maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD). Incruse received US and EU approvals for use in COPD in April 2014. GlaxoSmithKline has also developed umeclidinium in combination with the long-acting beta 2 agonist (LABA) vilanterol; the LABA/LAMA combination is marketed under the brand name Anoro.